TrianglePUBLICATIONS · 11331325
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2001 May 1
- First author
- Duvic M
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Duvic M
- type
- Author
- name
- Hymes K
- type
- Author
- name
- Heald P
- type
- Author
- name
- Breneman D
- type
- Author
- name
- Martin AG
- type
- Author
- name
- Myskowski P
- type
- Author
- name
- Crowley C
- type
- Author
- name
- Yocum RC
- type
- Author
- name
- Bexarotene Worldwide Study Group
- type
- CollectiveName
Complete bibliographic record and source provenance
- authors
- name
- Duvic M
- type
- Author
- name
- Hymes K
- type
- Author
- name
- Heald P
- type
- Author
- name
- Breneman D
- type
- Author
- name
- Martin AG
- type
- Author
- name
- Myskowski P
- type
- Author
- name
- Crowley C
- type
- Author
- name
- Yocum RC
- type
- Author
- name
- Bexarotene Worldwide Study Group
- type
- CollectiveName
- bibliography ids
- nci-bib-6e96677d0f3db9c20e700b10
- book metadata
- content sha256
- 42d803a0eddb192b05258211a6d1c4b9eceac114f099cab35e32ddf5a2cff6bb
- document type
- citation
- dois
- 10.1200/JCO.2001.19.9.2456
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:11331325
- immutable id
- pubmed:11331325@42d803a0eddb192b05258211a6d1c4b9eceac114f099cab35e32ddf5a2cff6bb
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- Source null
- issn print
- 0732-183X
- issue
- 9
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 2456-71
- volume
- 19
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 11331325
- provenance
- batch id
- 30d2cd7affbbb92b6784
- provider
- NCBI PubMed ESummary
- record sha256
- 7f47d8e558533dfd997d114df7c8477ad200dc44d7fa44357289ea717dd3c2ed
- response sha256
- ae7ed930f8b43c9e34eeae02f278f33f49c15777b81f742392c120eb64949120
- retrieved at
- 2026-09-09T23:45:39.779418+00:00
- publication date
- display
- 2001 May 1
- precision
- day
- year
- 2001
- publication types
- Clinical Trial
- Clinical Trial, Phase II
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Research Support, U.S. Gov't, P.H.S.
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
Preserved source evidence · Not medical advice